Clinical Trial Detail

NCT ID NCT04007029
Title Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Jonsson Comprehensive Cancer Center
Indications

diffuse large B-cell lymphoma

follicular lymphoma

mantle cell lymphoma

chronic lymphocytic leukemia

CLL/SLL

primary mediastinal B-cell lymphoma

Therapies

Tocilizumab

Anti-CD19-CD20 CAR T cells + Cyclophosphamide + Fludarabine

Age Groups: adult senior

No variant requirements are available.